Geoffrey Porges

How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?

Pfizer's COVID-19 Franchise Could Push Revenue Past $100B In 2022: Analyst

Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism

Pfizer's COVID-19 Franchise Could Push Revenue Past $100B In 2022: Analyst

Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism

What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict

14 Biotech Stocks To Watch Over The Next 6 Months

What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict

14 Biotech Stocks To Watch Over The Next 6 Months

Breaking Down Novavax's Coronavirus Vaccine Data: 2 Analysts Takes

Pfizer Analyst Breaks Down The FDA Process For Coronavirus Vaccine Candidate

Geoffrey Porges Recent News

AstraZeneca Analyst Flags Lack Of Details In Interim COVID-19 Vaccine Data

AstraZeneca plc (NASDAQ: AZN) announced Monday interim Phase 3 data for its coronavirus vaccine candidate AZD1222 from studies conducted in the U.K.

Pfizer Analysts Raise Odds Of Success For Coronavirus Vaccine Candidate To 100%

Pfizer Inc. (NYSE: PFE) reported Monday with strong Phase 3 interim efficacy data for its coronavirus vaccine candidate.

Pfizer's COVID-19 Vaccine Candidate Primed For $3.5B In 2021 Sales: Analyst

The mRNA coronavirus vaccine in development by Pfizer Inc.

Moderna, Pfizer Have 2-Month Lead Over Coronavirus Vaccine Competitors: Analyst

The coronavirus vaccine race has two likely winners that have surged ahead in a crowded field, according to an SVB Leerink analyst.

Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology'

Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc.

Gilead Analysts Downplay Q2 Miss Amid Remdesivir's COVID-19 Opportunity

Gilead Sciences, Inc. (NASDAQ: GILD) reported second-quarter revenues and earnings that trailed expectations. The Gilead Analysts

Pfizer Analysts See 'Surprisingly Strong' Vaccine Updates In Q2, Question Biopharma's Blockbuster Potential

Pfizer Inc. (NYSE: PFE) reported forecast-beating second-quarter results Tuesday and raised its full-year guidance.

Moderna Looking To Price Its Coronavirus Vaccine At $50-$60, Significantly Above Rivals: FT

Moderna Inc (NASDAQ: MRNA) is looking to price its COVID-19 vaccine significantly ahead of rivals in between $50 and $60 per course, the Financial Times reported Wednesday.

Moderna Analysts See Positives In Coronavirus Readout As Focus Shifts To Pivotal Phase 3 Study

Moderna Inc (NASDAQ: MRNA) shares awere bulldozing their way toward record highs Wednesday in reaction to the publication in the New England

4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize

The weekend was abuzz with rumors of U.K.

Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy

The consensus estimates for Gilead Sciences, Inc. (NASDAQ: GILD) appear overly conservative, especially given the prospects of remdesivir and products from the company’s recent collaboration with Arcus Biosciences Inc (NYSE:

Leerink: Translate Bio's Cystic Fibrosis Candidate Could Generate $1.8B

AbbVie Shares Double In A Year; Leerink Moves To Sidelines

Plenty Of Opportunity In AbbVie, Even After Recent Run

43% Upside Seen For Dova Pharma Following Competitor Product's Poor Results

Biogen's Catalysts May Be Waning; Leerink Downgrades To Market Perform

Alexion's Drug Trial Miss Doesn't Change Analysts' Long-Term Thesis

Alexion's Valuation Could Be Getting Pummeled Unnecessarily

Vertex Pharmaceuticals' Phase 3 Studies Offer Ample Opportunity For Upside

Gilead's HCV Franchise Erosion Here To Stay; Leerink Cuts Price Target

Jury Rules Merck Patents Valid…Bad For Gilead?

3 Mega Biotechs Leerink Loves

Is Gilead Sciences About To Buy Vertex For $45 Billion?